STN SEARCH TRANSCRIPT 10/622055

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * *     Welcome to STN International     * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   ACD predicted properties enhanced in REGISTRY/ZREGISTRY
 NEWS  4  OCT 03   MATHDI removed from STN
 NEWS  5  OCT 04   CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                   to core patent offices
 NEWS  6  OCT 06   STN AnaVist workshops to be held in North America
 NEWS  7  OCT 13   New CAS Information Use Policies Effective October 17, 2005
 NEWS  8  OCT 17   STN(R) AnaVist(TM), Version 1.01, allows the export/download
                   of CAplus documents for use in third-party analysis and
                   visualization tools
 NEWS  9  OCT 27   Free KWIC format extended in full-text databases
 NEWS 10  OCT 27   DIOGENES content streamlined
 NEWS 11  OCT 27   EPFULL enhanced with additional content
 NEWS 12  NOV 14   CA/CAplus - Expanded coverage of German academic research

 NEWS EXPRESS  NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * *  STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:37:54 ON 22 NOV 2005

=> FILE REG
COST IN U.S. DOLLARS                             SINCE FILE     TOTAL
                                                      ENTRY   SESSION
FULL ESTIMATED COST                                    0.21      0.21

FILE 'REGISTRY' ENTERED AT 10:38:11 ON 22 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

```
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    21 NOV 2005  HIGHEST RN 868586-21-4
DICTIONARY FILE UPDATES:   21 NOV 2005  HIGHEST RN 868586-21-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*******************************************************************
*                                                                 *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                 *
*******************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\Stnexp\Queries\PIPERAZINYL PYRAZINONES.str
```




```
chain nodes :
15  16
ring nodes :
1  2  3  4  5  6  9  10  11  12  13  14
chain bonds :
3-9  13-16  14-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-10  9-14  10-11  11-12  12-13  13-14
```

exact/norm bonds :
1-2 1-6 2-3 3-4 3-9 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 14-15
exact bonds :
13-16
isolated ring systems :
containing 1 : 9 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> D L1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 10:38:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 54 TO ITERATE

100.0% PROCESSED 54 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 640 TO 1520
PROJECTED ANSWERS: 8 TO 329

L3 8 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 10:38:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1266 TO ITERATE

100.0% PROCESSED 1266 ITERATIONS 134 ANSWERS
SEARCH TIME: 00.00.01

L4 134 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 10:38:42 ON 22 NOV 2005

FILE COVERS 1907 - 22 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 21 Nov 2005 (20051121/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L4
L5 1 L4

=> D

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:80683 CAPLUS
DN 140:128433
TI Preparation of piperazinyl-2(1H)-pyrazinones for treatment of 5-HT2A receptor-related disorders
IN Nilsson, Bjoern; Thor, Markus; Cernerud, Magnus; Lundstroem, Helena
PA Biovitrum Ab, Swed.
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004009586	A1	20040129	WO 2003-SE1102	20030625

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

```
          BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2492924          AA    20040129    CA 2003-2492924         20030625
     BR 2003012789       A     20050503    BR 2003-12789           20030625
     EP 1534391          A1    20050601    EP 2003-765414          20030625
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005533847       T2    20051110    JP 2004-522879          20030625
     US 2004063693       A1    20040401    US 2003-622055          20030717
PRAI SE 2002-2287        A     20020719
     US 2002-426240P     P     20021114
     WO 2003-SE1102      W     20030625
OS   MARPAT 140:128433
RE.CNT  8     THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY     SESSION
FULL ESTIMATED COST                             2.00     163.54

STN INTERNATIONAL LOGOFF AT 10:39:56 ON 22 NOV 2005


Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09  ACD predicted properties enhanced in REGISTRY/ZREGISTRY
 NEWS  4  OCT 03  MATHDI removed from STN
 NEWS  5  OCT 04  CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                  to core patent offices
 NEWS  6  OCT 06  STN AnaVist workshops to be held in North America
 NEWS  7  OCT 13  New CAS Information Use Policies Effective October 17, 2005
 NEWS  8  OCT 17  STN(R) AnaVist(TM), Version 1.01, allows the export/download
                  of CAplus documents for use in third-party analysis and
                  visualization tools
 NEWS  9  OCT 27  Free KWIC format extended in full-text databases
 NEWS 10  OCT 27  DIOGENES content streamlined
 NEWS 11  OCT 27  EPFULL enhanced with additional content
 NEWS 12  NOV 14  CA/CAplus - Expanded coverage of German academic research

 NEWS EXPRESS  NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability

 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:40:27 ON 22 NOV 2005

=> FILE MEDLINE
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY     SESSION
FULL ESTIMATED COST                             0.21       0.21

FILE 'MEDLINE' ENTERED AT 10:40:36 ON 22 NOV 2005

 FILE LAST UPDATED: 16 NOV 2005 (20051116/UP).  FILE COVERS 1950 TO DATE.

 On December 19, 2004, the 2005 MeSH terms were loaded.

 The MEDLINE reload for 2005 is now available.  For details enter HELP
 RLOAD at an arrow promt (=>).  See also:

    http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

 OLDMEDLINE now back to 1950.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2005 vocabulary.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> S 5HT2A ANTAG?
           150 5HT2A
        528367 ANTAG?
L1           9 5HT2A ANTAG?
                 (5HT2A(W)ANTAG?)

=> S 5HT ANTAG?
          2473 5HT
        528367 ANTAG?
L2           54 5HT ANTAG?
                 (5HT(W)ANTAG?)

=> S 5-HT ANTA?
       2140385 5
         31272 HT
           743 HTS
         31949 HT
                 (HT OR HTS)
        538343 ANTA?
L3         599 5-HT ANTA?
                 (5(W)HT(W)ANTA?)
```

APPLICANTS

ENABLEMENT

SEARCH -

5HT2A ANTAG!S

```
=> S L2 OR L1 OR L3
L4          661 L2 OR L1 OR L3

=> S L4 AND (2001/PY OR 2002/PY)
         518671 2001/PY
         541230 2002/PY
L5           22 L4 AND (2001/PY OR 2002/PY)

=> S 1-22
        3587146 1
         343498 22
L6        11321 1-22
                (1(W)22)

=> D L5 1-22

L5   ANSWER 1 OF 22     MEDLINE on STN
AN   2003153051     MEDLINE
DN   PubMed ID: 12656947
TI   Non-adrenergic non-cholinergic excitatory innervation in the airways: role
     of neurokinin-2 receptors.
AU   Krishnakumar S; Holmes E P; Moore R M; Kappel L; Venugopal C S
CS   Departments of Comparative Biomedical Sciences and Veterinary Clinical
     Sciences, School of Veterinary Medicine, Louisiana State University, Skip
     Bertman Drive, Baton Rouge, LA 70803, USA.
SO   Autonomic & autacoid pharmacology, (2002 Aug) 22 (4) 215-24.
     Journal code: 101157306. ISSN: 1474-8665.
CY   England: United Kingdom
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200309
ED   Entered STN: 20030403
     Last Updated on STN: 20030924
     Entered Medline: 20030923

L5   ANSWER 2 OF 22     MEDLINE on STN
AN   2003009984     MEDLINE
DN   PubMed ID: 12457458
TI   Serotonergic involvement in stress-induced vasopressin and oxytocin
     secretion.
AU   Jorgensen Henrik; Knigge Ulrich; Kjaer Andreas; Warberg Jorgen
CS   Department of Medical Physiology, The Panum Institute, Rigshospitalet,
     University of Copenhagen, Blegdamsvej 3, DK-2200N Copenhagen, Denmark..
     hsj@mfi.ku.dk
SO   European journal of endocrinology / European Federation of Endocrine
     Societies, (2002 Dec) 147 (6) 815-24.
     Journal code: 9423848. ISSN: 0804-4643.
CY   England: United Kingdom
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200301
ED   Entered STN: 20030109
     Last Updated on STN: 20030125
     Entered Medline: 20030124

L5   ANSWER 3 OF 22     MEDLINE on STN
AN   2002704529     MEDLINE
DN   PubMed ID: 12444818
TI   Nefazodone treatment of pathological gambling: a prospective open-label
     controlled trial.
AU   Pallanti Stefano; Baldini Rossi Nicolo; Sood Erica; Hollander Eric
CS   Department of Psychiatry, Mount Sinai School of Medicine, New York, N.Y.,
     USA.
SO   Journal of clinical psychiatry, (2002 Nov) 63 (11) 1034-9.
     Journal code: 7801243. ISSN: 0160-6689.
CY   United States
DT   (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200212
ED   Entered STN: 20021217
     Last Updated on STN: 20021227
     Entered Medline: 20021226

L5   ANSWER 4 OF 22     MEDLINE on STN
AN   2002354397     MEDLINE
DN   PubMed ID: 12097192
TI   Serotonin antagonist profiling on 5HT2A and 5HT2C receptors by
     nonequilibrium intracellular calcium response using an automated
     flow-through fluorescence analysis system, HT-PS 100.
AU   Kaler Gregory; Otto Michael; Okun Alex; Okun Ilya
CS   Axiom Biosciences, AXIOM Biotechnologies, Inc., San Diego, CA 92121, USA..
     gkaler@axiombio.com
SO   Journal of biomolecular screening : official journal of the Society for
     Biomolecular Screening, (2002 Jun) 7 (3) 291-301.
     Journal code: 9612112. ISSN: 1087-0571.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200301
ED   Entered STN: 20020707
     Last Updated on STN: 20030117
     Entered Medline: 20030116

L5   ANSWER 5 OF 22     MEDLINE on STN
AN   2002335689     MEDLINE
DN   PubMed ID: 12061865
TI   Changes in serotonin, serotonin transporter expression and serotonin
     denervation supersensitivity: involvement in chronic central pain after
     spinal hemisection in the rat.
AU   Hains Bryan C; Everhart Alex W; Fullwood Steven D; Hulsebosch Claire E
CS   Department of Anatomy and Neurosciences, Marine Biomedical Institute,
     University of Texas Medical Branch, 301 University Boulevard, Galveston
     77555-1043, USA.
NC   NS11255 (NINDS)
     NS39161 (NINDS)
SO   Experimental neurology, (2002 Jun) 175 (2) 347-62.
     Journal code: 0370712. ISSN: 0014-4886.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200207
ED   Entered STN: 20020625
     Last Updated on STN: 20020716
     Entered Medline: 20020715

L5   ANSWER 6 OF 22     MEDLINE on STN
AN   2002284465     MEDLINE
DN   PubMed ID: 12022444
TI   Muramyl dipeptide (MDP) and 5-HT receptors. Neuroimmunomodulatory effects
     of MDP are probably not mediated through 5-HT4 or 5-HT1A receptors.
AU   Sevcik Jan; Ruicka Vladimir; Slainsky Josef; Masek Karel
CS   Institute of Pharmacology, Academy of Sciences of the Czech Republic,
     Prague.. sevcik@biomed.cas.cz
SO   Immunopharmacology and immunotoxicology, (2002 Feb) 24 (1)
```

43-53.
Journal code: 8800150. ISSN: 0892-3973.
CY United States
DT Journal; Article; (JOURNAL ARTIGLE)
LA English
FS Priority Journals
EM 200212
ED Entered STN: 20020528
Last Updated on STN: 20030118
Entered Medline: 20021204

L5 ANSWER 7 OF 22 MEDLINE on STN
AN 2002210385 MEDLINE
DN PubMed ID: 11906971
TI The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.
AU Krobert Kurt A; Levy Finn Olav
CS MSD Cardiovascular Research Center, University of Oslo, Rikshospitalet University Hospital, Blindern, N-0316 Oslo, Norway.
SO British journal of pharmacology, **(2002 Mar)** 135 (6) 1563-71.
Journal code: 7502536. ISSN: 0007-1188.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200207
ED Entered STN: 20020412
Last Updated on STN: 20020712
Entered Medline: 20020710

L5 ANSWER 8 OF 22 MEDLINE on STN
AN 2002142176 MEDLINE
DN PubMed ID: 11861321
TI 5-HT(1B) but not 5-HT(6) or 5-HT(7) receptors mediate depression of spinal nociceptive reflexes in vitro.
AU Hedo G; Lopez-Garcia J A
CS Departamento de Fisiologia, Edificio de Medicina, Universidad de Alcala, Madrid 28871, Spain.
SO British journal of pharmacology, **(2002 Feb)** 135 (4) 935-42.
Journal code: 7502536. ISSN: 0007-1188.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200212
ED Entered STN: 20020307
Last Updated on STN: 20021227
Entered Medline: 20021226

L5 ANSWER 9 OF 22 MEDLINE on STN
AN 2002048958 MEDLINE
DN PubMed ID: 11772289
TI Advances in pharmacological treatment of migraine.
AU Diener H C; Limmroth V
CS Department of Neurology, University Essen, Hufelandstr. 55, 45122 Essen, Germany.. h.diener@uni-essen.de
SO Expert opinion on investigational drugs, **(2001 Oct)** 10 (10) 1831-45. Ref: 177
Journal code: 9434197. ISSN: 1354-3784.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200202
ED Entered STN: 20020125
Last Updated on STN: 20020301
Entered Medline: 20020228

L5 ANSWER 10 OF 22 MEDLINE on STN
AN 2002035082 MEDLINE
DN PubMed ID: 11763004
TI The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia.
AU Scheepers F E; Gespen de Wied C C; Kahn R S
CS University Medical Center, Department of Psychiatry, Utrecht, The Netherlands.. f.scheepers@psych.azu.nl
SO Journal of clinical psychopharmacology, **(2001 Dec)** 21 (6) 575-82.
Journal code: 8109496. ISSN: 0271-0749.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200205
ED Entered STN: 20020124
Last Updated on STN: 20020508
Entered Medline: 20020507

L5 ANSWER 11 OF 22 MEDLINE on STN
AN 2002000064 MEDLINE
DN PubMed ID: 11737145
TI Serotonin localization in Phallusia mammillata larvae and effects of **5-HT antagonists** during larval development.
AU Pennati R; Groppelli S; Sotgia C; Candiani S; Pestarino M; De Bernardi F
CS Department of Biology, Section of Zoology SN 7B, University of Milano, via Celoria 26, 20133 Milano, Italy.. sirob@mailserver.unimi.it
SO Development, growth & differentiation, **(2001 Dec)** 43 (6) 647-56.
Journal code: 0356504. ISSN: 0012-1592.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 20020102
Last Updated on STN: 20020404
Entered Medline: 20020402

L5 ANSWER 12 OF 22 MEDLINE on STN
AN 2001689421 MEDLINE
DN PubMed ID: 11717237
TI Serotonin elicits long-lasting enhancement of rhythmic respiratory activity in turtle brain stems in vitro.
AU Johnson S M; Wilkerson J E; Henderson D R; Wenninger M R; Mitchell G S
CS Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden Dr. West, Madison, WI 53706, USA.. johnsons@svm.vetmed.wisc.edu
NC HL-36780 (NHLBI)
HL-60028 (NHLBI)
SO Journal of applied physiology (Bethesda, Md. : 1985), **(2001 Dec)** 91 (6) 2703-12.
Journal code: 8502536. ISSN: 8750-7587.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200202
ED Entered STN: 20011212

Last Updated on STN: 20030118
Entered Medline: 20020212

L5 ANSWER 13 OF 22 MEDLINE on STN
AN 2001683032 MEDLINE
DN PubMed ID: 11728834
TI Effects of the **5HT antagonist** cyproheptadine on neuropsychological function in chronic schizophrenia.
AU Chaudhry I B; Soni S D; Hellewell J S E; Deakin J F W
CS Rossendale Hospital, Haslingden Road, Rawtenstall BB4 6NE, UK.
SO Schizophrenia research, **(2002 Jan 1)** 53 (1-2) 17-24.
Journal code: 8804207. ISSN: 0920-9964.
CY Netherlands
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200202
ED Entered STN: 20011203
Last Updated on STN: 20020223
Entered Medline: 20020222

L5 ANSWER 14 OF 22 MEDLINE on STN
AN 2001644973 MEDLINE
DN PubMed ID: 11697445
TI Investigations on possible serotonergic involvement in effects of OB-200G (polyherbal preparation) on food intake in female mice.
AU Kaur G; Kulkarni S K
CS Pharmacology Division, Univ Inst Pharm Sci, Panjab University, Chandigarh, India.
SO European journal of nutrition, **(2001 Jun)** 40 (3) 127-33.
Journal code: 100888704. ISSN: 1436-6207.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 20011108
Last Updated on STN: 20020123
Entered Medline: 20011205

L5 ANSWER 15 OF 22 MEDLINE on STN
AN 2001528219 MEDLINE
DN PubMed ID: 11573989
TI Engraftment of serotonergic precursors enhances locomotor function and attenuates chronic central pain behavior following spinal hemisection injury in the rat.
AU Hains B C; Johnson K M; McAdoo D J; Eaton M J; Hulsebosch C E
CS Department of Anatomy and Neurosciences and Marine Biomedical Institute, University of Texas Medical Branch, Galveston, Texas 77555-1069, USA.
NC NS11255 (NINDS)
NS39161 (NINDS)
SO Experimental neurology, **(2001 Oct)** 171 (2) 361-78.
Journal code: 0370712. ISSN: 0014-4886.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 20011001
Last Updated on STN: 20020122
Entered Medline: 20011205

L5 ANSWER 16 OF 22 MEDLINE on STN
AN 2001505635 MEDLINE
DN PubMed ID: 11522602
TI The plasma protein extravasation induced by adenosine and its analogues in the rat dorsal skin: evidence for the involvement of capsaicin sensitive primary afferent neurones and mast cells.
AU Esquisatto L C; Costa S K; Camargo E A; Ribela M T; Brain S D; de Nucci G; Antunes E
CS Department of Pharmacology, Faculty of Medical Sciences, UNICAMP, PO Box 6111, 13081-970, Campinas, (SP), Brazil.
SO British journal of pharmacology, **(2001 Sep)** 134 (1) 108-15.
Journal code: 7502536. ISSN: 0007-1188.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 20010917
Last Updated on STN: 20011015
Entered Medline: 20011011

L5 ANSWER 17 OF 22 MEDLINE on STN
AN 2001493317 MEDLINE
DN PubMed ID: 11535663
TI Voltage-sensitivity of motoneuron NMDA receptor channels is modulated by serotonin in the neonatal rat spinal cord.
AU MacLean J N; Schmidt B J
CS Department of Physiology, University of Manitoba, 730 William Ave., Winnipeg, Manitoba R3E 3J7, Canada.
SO Journal of neurophysiology, **(2001 Sep)** 86 (3) 1131-8.
Journal code: 0375404. ISSN: 0022-3077.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 20010906
Last Updated on STN: 20020122
Entered Medline: 20011204

L5 ANSWER 18 OF 22 MEDLINE on STN
AN 2001459934 MEDLINE
DN PubMed ID: 11302287
TI Drug treatment options for irritable bowel syndrome: managing for success.
AU Dunphy R C; Verne G N
CS Department of Medicine, University of Florida, Gainesville, USA.
SO Drugs & aging, **(2001)** 18 (3) 201-11. Ref: 61
Journal code: 9102074. ISSN: 1170-229X.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200108
ED Entered STN: 20010820
Last Updated on STN: 20010820
Entered Medline: 20010816

L5 ANSWER 19 OF 22 MEDLINE on STN
AN 2001421938 MEDLINE
DN PubMed ID: 11247051
TI The effects of ondansetron on sleep-disordered breathing in the English bulldog.
AU Veasey S C; Chachkes J; Fenik P; Hendricks J C
CS Center for Sleep & Respiratory Neurobiology, Department of Medicine,

School of Medicine, University of Pennsylvania, 19104-4283, USA..
veasey@mail.med.upenn.edu
NC HL-60287 (NHLBI)
SO Sleep, **(2001 Mar 15)** 24 (2) 155-60.
Journal code: 7809084. ISSN: 0161-8105.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200107
ED Entered STN: 20010730
Last Updated on STN: 20010730
Entered Medline: 20010726

L5 ANSWER 20 OF 22 MEDLINE on STN
AN 2001261151 MEDLINE
DN PubMed ID: 11294747
TI Interaction of serotonin and cholecystokinin in the lateral parabrachial nucleus to control sodium intake.
AU Fratucci De Gobbi J I; De Luca L A Jr; Johnson A K; Menani J V
CS Department of Physiology and Pathology, School of Dentistry, Paulista State University (UNESP), 14801 - 903 Araraquara, Sao Paulo, Brazil.
NC HL-14388 (NHLBI)
HL-57472 (NHLBI)
SO American journal of physiology. Regulatory, integrative and comparative physiology, **(2001 May)** 280 (5) R1301-7.
Journal code: 100901230. ISSN: 0363-6119.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Space Life Sciences
EM 200105
ED Entered STN: 20010521
Last Updated on STN: 20011023
Entered Medline: 20010517

L5 ANSWER 21 OF 22 MEDLINE on STN
AN 2001185784 MEDLINE
DN PubMed ID: 11277605
TI Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats.
AU Sanchez H; Velazquez-Martinez D N
CS Departamento de Psicofisiologia, Facultad de Psicologia, Universidad Nacional Autonoma de Mexico, Mexico DF.
SO Journal of psychopharmacology (Oxford, England), **(2001 Mar)** 15 (1) 29-36.
Journal code: 8907828. ISSN: 0269-8811.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200107
ED Entered STN: 20010723
Last Updated on STN: 20030118
Entered Medline: 20010719

L5 ANSWER 22 OF 22 MEDLINE on STN
AN 2001140842 MEDLINE
DN PubMed ID: 11161597
TI Serotonin modifies the neuronal inhibitory responses to gamma-aminobutyric acid in the red nucleus: a microiontophoretic study in the rat.
AU Licata F; Li Volsi G; Di Mauro M; Fretto G; Ciranna L; Santangelo F
CS Department of Physiological Sciences, University of Catania, Catania, 95125, Italy.
SO Experimental neurology, **(2001 Jan)** 167 (1) 95-107.
Journal code: 0370712. ISSN: 0014-4886.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200103
ED Entered STN: 20010404
Last Updated on STN: 20030118
Entered Medline: 20010308

=> D ABS 18

L6 ANSWER 18 OF 11321 MEDLINE on STN
AB CONTEXT: Medullary thyroid carcinoma (MTC) is a characteristic tumor occurring in individuals with multiple endocrine neoplasia type 2 who carry germ-line mutations in RET (rearranged during transfection). However, most MTC occur in individuals without a family history. OBJECTIVES: The objective of this study was to explore the possibility that susceptibility in these cases results from low penetrance alleles of RET, its coreceptors, and ligands. DESIGN: We carried out an association study in 135 sporadic MTC (sMTC) patients and 533 controls from the United Kingdom population. RESULTS AND CONCLUSIONS: We analyzed 33 polymorphisms in all nine genes involved in the glial cell line-derived neurotropic factor receptor-alpha (GFRalpha)-RET complex. This is the first association study in which all genes involved in this complex have been investigated for susceptibility to sMTC. We did not find any association between single nucleotide polymorphisms in the exonic regions of the GFRalpha2, GFRalpha3, GFRalpha4, glial cell line-derived neurotropic factor, neurturin, or persephin genes and risk of developing sMTC. We found a strong association between the disease and specific haplotypes of RET. We not only confirmed the previously described association with G691S and S904S (for heterozygotes: odds ratio, 1.85; range, **1.22**-2.82; P = 0.004), but we found a novel protective effect associated with a specific haplotype (odds ratio, 0.39; range, 0.21-0.72; P = 0.005) revealing the existence of different genetic variants in the RET oncogene that either increase or decrease risk of sMTC.

=> D L5 ABS 18

L5 ANSWER 18 OF 22 MEDLINE on STN
AB Irritable bowel syndrome (IBS) is a functional gut disorder the diagnosis of which is based on clinical symptoms as set forth by the Rome criteria. As the population ages, especially with the population of patients >75 years of age expanding greatly over the next 10 years, IBS is becoming one of the most common diseases of the elderly. Thus far, developing treatment strategies for patients with IBS has been difficult because of the lack of pharmacological targets and the wide range of symptomatology. Additionally, demonstration of a therapeutic benefit is difficult in the presence of a high placebo response observed regardless of the therapy employed. Fibre, antidiarrhoeals and antispasmodics all play some role in the symptomatic treatment of IBS. With the evolution of IBS as a disorder of visceral hypersensitivity, new drugs have been developed that target the enteric nervous system. Tricyclic antidepressants (TCAs) have been found to target the enteric neurons and play a role in pain modulation. Currently, the TCAs are recommended only for severe cases of IBS pain. The newest class of drugs to be approved for use in IBS are the serotonin (5-hydroxytryptamine; **5-HT**) **antagonists**. Specifically, the 5-HT3 receptor antagonists have been shown to decrease symptoms in female patients with IBS. A related class of drugs, the 5-HT4 receptor agonists, is being developed for the treatment of constipation-predominant IBS. Further investigation into the role of spinal afferent neurons in visceral hypersensitivity is at the forefront of IBS research. Several experimental drug therapies for IBS are also

discussed in this review including N-methyl-D-aspartate receptor antagonists, neurokinin-1 receptor antagonists, octreotide, clonidine and the selective M3 receptor antagonist, zamifenacin.

=> D L5 ABS 9, 10

L5 ANSWER 9 OF 22 MEDLINE on STN
AB Migraine is a paroxysmal disorder with attacks of headache, nausea, vomiting, photo- and phonophobia and malaise. This review summarises new treatment options both for the therapy of the acute attack as well as for migraine prophylaxis. Analgesics like aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) are effective in treating migraine attacks. Few controlled trials were performed for the use of ergotamine or dihydroergotamine. These trials indicate inferior efficacy compared with serotonin (5-HT(1B/D)) agonists (triptans). The triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan), are highly effective. They improve headache as well as nausea, photo- and phonophobia. The different triptans show only minor differences in efficacy, headache recurrence and adverse effects. The knowledge of their different pharmacological profile allows a more specific treatment of the individual migraine characteristics. Migraine prophylaxis is recommended, when more than three attacks occur per month, if attacks do not respond to acute treatment or if side effects of acute treatment are severe. Substances with proven efficacy include the beta-blockers metoprolol and propranolol, the calcium channel blocker flunarizine, several **5-HT antagonists** and amitriptyline. Recently anti-epileptic drugs (valproic acid, gabapentin, topiramate) were evaluated for the prophylaxis of migraine. The use of botulinum toxin is under investigation.

L5 ANSWER 10 OF 22 MEDLINE on STN
AB In addition to dopamine, serotonin (5-hydroxytryptamine, 5-HT) has been reported to play an important role in schizophrenia. Besides blocking dopamine, atypical antipsychotics also block 5-HT receptors. The clinical efficacy of the atypical antipsychotic clozapine is associated with the **5-HT antagonistic** action of the drug and a high serotonergic tone before treatment. The atypical antipsychotic olanzapine has a receptor-binding profile similar to that of clozapine. The present study investigated whether treatment with olanzapine blocks hormone release induced by the 5-HT2c agonist m-chlorophenylpiperazine (m-CPP) and, if so, whether this **5-HT antagonistic** effect is related to treatment response. Eighteen male schizophrenic patients participated in this study. All patients were challenged with m-CPP (0.5 mg/kg orally) in a double-blind, randomized, placebo-controlled design after a drug-free period of at least 2 weeks. Adrenocorticotropic hormone (ACTH), cortisol, and prolactin plasma levels were measured every 30 minutes up to 210 minutes after challenge. Patients were treated for 6 weeks with 10 mg olanzapine daily in an open design, after which the challenge tests were repeated. Olanzapine significantly blocked m-CPP-induced ACTH, cortisol, and prolactin release, suggesting that it is a potent 5-HT2c antagonist in vivo. This 5 **-HT antagonistic** effect of olanzapine was not significantly correlated with treatment response. Also, no significant correlation was found between m-CPP-induced hormone release before treatment and clinical response after treatment with olanzapine. These findings suggest that olanzapine is a potent 5-HT2c antagonist in vivo but that this is unrelated to its clinical efficacy in this nonrefractory sample of schizophrenic patients.

=> D L5 ABS 3'
'3'' IS NOT A VALID FORMAT FOR FILE 'MEDLINE'

The following are valid formats:

The default display format is BIB.

```
ABS ---- AB
ALL ---- AN, DN, TI, CM, AU, CS, NC, SO, CY, DT, LA, FS, OS, EM,
         ED, AB, ST, CT, NA, RN, CN, GEN
BIB ---- AN, DN, TI, CM, AU, CS, NC, SO, CY, DT, LA, FS, OS, EM, ED
CBIB --- AN, DN, TI, CM, AU, CS, NC, SO, CY, DT, LA, FS, OS, EM, ED
DALL --- ALL, delimited for post processing
IABS --- ABS, with a text label
IALL --- ALL, indented with text labels
IBIB --- BIB, indented with text labels
IND ---- ST, CT, NA, RN, CN, GEN
SAM ---- TI, CM, ST, CT, NA, RN, CN, GEN
TRI ---- TI, CM, ST, CT, NA, RN, CN, GEN
TRIAL -- TI, CM, ST, CT, NA, RN, CN, GEN
HIT ---- All fields containing hit terms
HITIND - IND
KWIC --- All hit terms plus 20 words on either side
OCC ---- List of display fields containing hit terms
```

Hit terms will be highlighted in all available fields except CM and PY.

To display a particular field or fields, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an arrow prompt (=>). Examples of formats include: 'BIB'; 'AB'; 'SO,ST'. You may specify the format fields in any order, and the information will be displayed in the same order as the format specification.

The same formats (except for HIT, HITIND, KWIC, and OCC) may be used with the DISPLAY ACC command to display the record for a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):END

=> D L5 ABS 3

L5 ANSWER 3 OF 22 MEDLINE on STN
AB BACKGROUND: Pathological gambling is a disabling and highly prevalent impulse-control disorder not otherwise specified (NOS). According to the hypothesis of abnormal serotonin function in the pathophysiology of poor impulse control and pathological gambling, we assessed the efficacy and tolerability of nefazodone, a **5-HT antagonist** reported to be effective in other impulse-control disorders NOS, in the treatment of pathological gambling. METHOD: Fourteen outpatients who met DSM-IV criteria for pathological gambling were enrolled in a prospective 8-week open-label oral nefazodone trial. Nefazodone was initiated at 50 mg/day and titrated upward to a maximum of 500 mg/day based on patient's response and side effects, with a minimum daily dose of 100 mg. Improvement in gambling was assessed via the pathological gambling modifications of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS), the Clinical Global Impressions-Improvement scale (PG-CGI-I), and self-rated gambling scales. Response was defined a priori as both a 25% reduction in PG-YBOCS score and a score of 1 (very much improved) or 2 (much improved) on the PG-CGI-I scale. RESULTS: Twelve subjects completed the study, and 2 subjects were early dropouts who did not receive the minimum required dose. Significant improvements were noted in all gambling outcome measures, as well as in depression and anxiety ratings (which did not significantly correlate with gambling reduction). Nine (75%) of 12 patients were rated as responders according to a priori criteria. Side effects (dry mouth and sedation) of moderate severity occurred in 4 subjects. CONCLUSION: These preliminary results suggest that nefazodone may be effective in reducing symptoms of pathological gambling and is well tolerated.

```
=> S 5-HT2A
      2140385 5
         2290 HT2A
L7       2277 5-HT2A
               (5(W)HT2A)

=> S L7 AND ANTAG?
       528367 ANTAG?
L8       1354 L7 AND ANTAG?

=> S L8 AND (2001/PY OR 2002/PY)
       518671 2001/PY
       541230 2002/PY
L9        237 L8 AND (2001/PY OR 2002/PY)

=> S L9 NOT L5
L10       236 L9 NOT L5

=> S L10 AND (CLINI? OR THERA?)
      1655150 CLINI?
      2758974 THERA?
L11        62 L10 AND (CLINI? OR THERA?)

=> S L11 AND REVIEW
       416722 REVIEW
        52232 REVIEWS
       457346 REVIEW
                (REVIEW OR REVIEWS)
L12         4 L11 AND REVIEW

=> D 1-4

L12  ANSWER 1 OF 4     MEDLINE on STN
AN   2002639063     MEDLINE
DN   PubMed ID: 12397861
TI   Risperidone: review of its therapeutic utility in
     depression.
AU   Myers J E; Thase M E
CS   Janssen Pharmaceutical, Titusville, NJ, USA.
SO   Psychopharmacology bulletin, (2001 Autumn) 35 (4) 109-29.  Ref:
     55
     Journal code: 0101123. ISSN: 0048-5764.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     (REVIEW, TUTORIAL)
LA   English
FS   Priority Journals
EM   200211
ED   Entered STN: 20021026
     Last Updated on STN: 20021211
     Entered Medline: 20021113

L12  ANSWER 2 OF 4     MEDLINE on STN
AN   2002311949     MEDLINE
DN   PubMed ID: 12054060
TI   5-HT2A antagonists in psychiatric disorders.
AU   de Angelis Luisa
CS   Department of Biomedical Sciences, University of Trieste, Italy..
     ldeangelis@spin.it
SO   Current opinion in investigational drugs (London, England : 2000),
     (2002 Jan) 3 (1) 106-12.  Ref: 63
     Journal code: 100965718. ISSN: 1472-4472.
CY   England: United Kingdom
DT   Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     (REVIEW, TUTORIAL)
LA   English
FS   Priority Journals
EM   200212
ED   Entered STN: 20020611
     Last Updated on STN: 20021218
     Entered Medline: 20021217

L12  ANSWER 3 OF 4     MEDLINE on STN
AN   2002104850     MEDLINE
DN   PubMed ID: 11836973
TI   Estrogenic modulation of brain activity: implications for schizophrenia
     and Parkinson's disease.
AU   Cyr Michel; Calon Frederic; Morissette Marc; Di Paolo Therese
CS   Oncology and Molecular Endocrinology Research Centre, Faculte de
     pharmacie, Universite Laval, Sainte-Foy, Que.
SO   Journal of psychiatry & neuroscience : JPN, (2002 Jan) 27 (1)
     12-27.  Ref: 211
     Journal code: 9107859. ISSN: 1180-4882.
CY   Canada
DT   Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     (REVIEW, TUTORIAL)
LA   English
FS   Priority Journals
EM   200204
ED   Entered STN: 20020212
     Last Updated on STN: 20020410
     Entered Medline: 20020409

L12  ANSWER 4 OF 4     MEDLINE on STN
AN   2001148942     MEDLINE
DN   PubMed ID: 11212595
TI   Quetiapine and obsessive-compulsive symptoms (OCS): case report and
     review of atypical antipsychotic-induced OCS.
AU   Khullar A; Chue P; Tibbo P
CS   University of Alberta, Edmonton, Alta.
SO   Journal of psychiatry & neuroscience : JPN, (2001 Jan) 26 (1)
     55-9.
     Journal code: 9107859. ISSN: 1180-4882.
CY   Canada
DT   (CASE REPORTS)
     Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200103
ED   Entered STN: 20010404
     Last Updated on STN: 20010404
     Entered Medline: 20010315


=> D ABS 2

L12  ANSWER 2 OF 4     MEDLINE on STN
AB   Several lines of evidence support a role for serotoninergic (5-HT) system
     abnormalities in the pathogenesis and treatment of several psychiatric
     disorders.  This review summarizes information about the
     association between the 5-HT2A receptor gene and its
     relevance to schizophrenia, tardive dyskinesia, major depression,
     suicidality, anorexia nervosa and obsessive-compulsive disorder.  Evidence
     is presented that implies that selective 5-HT2A
     antagonists may be considered useful in investigating the role of
```

5-HT2A receptor function and in the treatment of psychosis, and possibly alcohol and cocaine dependence. Additionally, findings are reviewed on the importance of **5-HT2A** receptor **antagonism** in contributing to the **therapeutic** effect of several **clinically** effective and potential atypical antipsychotics as well as several antidepressants. In conclusion, the ability of selective **5-HT2A** receptor **antagonists** to interfere with the heightened state of dopamine activity without altering basal tone, suggests that these drugs possess antipsychotic activity and may provide the basis for new **therapies** for psychosis and drug dependence, in addition to contributing towards a more complete understanding of **5-HT2A** receptor function.

=> D ABS

L12 ANSWER 1 OF 4 MEDLINE on STN
AB There is extensive evidence to implicate dysregulation of noradrenergic, serotonergic, and dopaminergic neurotransmission in the pathophysiology of mood disorders. The receptor profile for risperidone, an atypical antipsychotic with demonstrated efficacy in schizophrenia, is consistent with possible antidepressant activity. Specifically, risperidone is a potent **antagonist** of central **5-HT2A** receptors, addressing symptoms such as insomnia, agitation, and weight loss and may indirectly enhance 5-HT1A-mediated neurotransmission. A search of the worldwide medical literature published through December 2000 revealed 24 publications pertinent to the **clinical** use of risperidone in the treatment of patients with depressive symptomatology. In schizophrenia, in which depression is a common comorbid condition, the results of eight randomized, blinded, and controlled trials consistently demonstrated that treatment with risperidone significantly reduced scores on various measures of depressive symptoms. Moreover, these effects were distinct from improvements in negative and positive symptoms. Antidepressant effects also were observed in two large meta-analyses of trials in patients with schizophrenia or schizoaffective disorder. Observations from uncontrolled studies and case reports of risperidone **therapy** of other psychiatric disorders were similarly suggestive of antidepressant activity. Collectively, the evidence we present in this **review** indicates that risperidone's **therapeutic** benefits in psychiatric medicine extend beyond potent and effective antipsychotic activity and may include effectiveness in treating depression and related affective disorders. Systematic studies are now needed to evaluate the utility of concomitant **therapy** with an atypical antipsychotic in psychotic, bipolar, and treatment-resistant depressive syndromes.

=> S L8 AND 2000/PY
489361 2000/PY
L13 107 L8 AND 2000/PY

=> S L13 AND (THERA? OR CLINI?)
2758974 THERA?
1655150 CLINI?
L14 23 L13 AND (THERA? OR CLINI?)

=> S L14 AND REVIEW
416722 REVIEW
52232 REVIEWS
457346 REVIEW
(REVIEW OR REVIEWS)
L15 1 L14 AND REVIEW

=> D

L15 ANSWER 1 OF 1 MEDLINE on STN
AN 2001036398 MEDLINE
DN PubMed ID: 10939309
TI Risperidone: a **review** of its use in the management of the behavioural and psychological symptoms of dementia.
AU Bhana N; Spencer C M
CS Adis International Limited, Mairangi Bay, Auckland, New Zealand.. demail@adis.co.nz
SO Drugs & aging, **(2000 Jun)** 16 (6) 451-71. Ref: 74
Journal code: 9102074. ISSN: 1170-229X.
CY New Zealand
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200011
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001130

=> S L14 NOT L15
L16 22 L14 NOT L15

=> D 1-22

L16 ANSWER 1 OF 22 MEDLINE on STN
AN 2001447861 MEDLINE
DN PubMed ID: 11072763
TI Novel antipsychotics and extrapyramidal side effects. Theory and reality.
AU Horacek J
CS Prague Psychiatric Centre and the 3rd Faculty of Medicine of Charles University, Czech Republic.. horacek@PCP.LF3.CUNI.CZ
SO Pharmacopsychiatry, **(2000 Sep)** 33 Suppl 1 34-42. Ref: 87
Journal code: 8402938. ISSN: 0176-3679.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200108
ED Entered STN: 20010813
Last Updated on STN: 20010813
Entered Medline: 20010809

L16 ANSWER 2 OF 22 MEDLINE on STN
AN 2001213803 MEDLINE
DN PubMed ID: 11081993
TI Effects of sesquiterpenoids from "Oriental incenses" on acetic acid-induced writhing and D2 and **5-HT2A** receptors in rat brain.
AU Okugawa H; Ueda R; Matsumoto K; Kawanishi K; Kato K
CS Institute for Oriental Medicine, Hyogo, Amagasaki, Hyogo, Japan.
SO Phytomedicine : international journal of phytotherapy and phytopharmacology, **(2000 Oct)** 7 (5) 417-22.
Journal code: 9438794. ISSN: 0944-7113.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200104
ED Entered STN: 20010425
Last Updated on STN: 20010425

Entered Medline: 20010419

L16 ANSWER 3 OF 22 MEDLINE on STN
AN 2001179156 MEDLINE
DN PubMed ID: 11206702
TI Dopamine D4 receptors and development of newer antipsychotic drugs.
AU Kulkarni S K; Ninan I
CS Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.. skpu@yahoo.com
SO Fundamental & clinical pharmacology, **(2000 Nov-Dec)** 14 (6) 529-39. Ref: 107
Journal code: 8710411. ISSN: 0767-3981.
CY France
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 200103
ED Entered STN: 20010404
Last Updated on STN: 20010404
Entered Medline: 20010329

L16 ANSWER 4 OF 22 MEDLINE on STN
AN 2001084926 MEDLINE
DN PubMed ID: 10969987
TI 1-[2-[(Heteroarylmethoxy)aryl]carbamoyl}indolines are selective and orally active 5-HT2C receptor inverse agonists.
AU Bromidge S M; Davies S; Duckworth D M; Forbes I T; Jones G E; Jones J; King F D; Blackburn T P; Holland V; Kennett G A; Lightowler S; Middlemiss D N; Riley G J; Trail B; Wood M D
CS SmithKline Beecham Pharmaceuticals, Discovery Research, Harlow, Essex, UK.. steve bromidge-1@sbphrd.com
SO Bioorganic & medicinal chemistry letters, **(2000 Aug 21)** 10 (16) 1867-70.
Journal code: 9107377. ISSN: 0960-894X.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200101
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010118

L16 ANSWER 5 OF 22 MEDLINE on STN
AN 2001073983 MEDLINE
DN PubMed ID: 11050288
TI LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor **antagonist**: a comparison with the antidepressant, nefazodone.
AU Pullar I A; Carney S L; Colvin E M; Lucaites V L; Nelson D L; Wedley S
CS Eli Lilly and Company, Lilly Research Centre Ltd., Erl Wood Manor, Surrey GU20 6PH, Windlesham, UK.. pullar@lilly.com
SO European journal of pharmacology, **(2000 Oct 27)** 407 (1-2) 39-46.
Journal code: 1254354. ISSN: 0014-2999.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200012
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001229

L16 ANSWER 6 OF 22 MEDLINE on STN
AN 2001054063 MEDLINE
DN PubMed ID: 10928313
TI High 5HT2A receptor occupancy in M100907-treated schizophrenic patients.
AU Talvik-Lotfi M; Nyberg S; Nordstrom A L; Ito H; Halldin C; Brunner F; Farde L
CS Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden.. mirjaml@psyk.ks.se
SO Psychopharmacology, **(2000 Mar)** 148 (4) 400-3.
Journal code: 7608025. ISSN: 0033-3158.
CY GERMANY: Germany, Federal Republic of
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200012
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001212

L16 ANSWER 7 OF 22 MEDLINE on STN
AN 2001016005 MEDLINE
DN PubMed ID: 10980325
TI Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment.
AU Govitrapong P; Chagkutip J; Turakitwanakan W; Srikiatkhachorn A
CS Neuro-Behavioural Biology Center, Institute of Science and Technology for Research and Development, Mahidol University, Salaya, 73170, Nakornpathom, Thailand.. grpkk@mahidol.ac.th
SO Psychiatry research, **(2000 Sep 25)** 96 (1) 41-50.
Journal code: 7911385. ISSN: 0165-1781.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200010
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001031

L16 ANSWER 8 OF 22 MEDLINE on STN
AN 2000484256 MEDLINE
DN PubMed ID: 10867971
TI Risperidone counteracts lethality in an animal model of the serotonin syndrome.
AU Nisijima K; Yoshino T; Ishiguro T
CS Department of Psychiatry, Jichi Medical School, Tochigi-Ken, Japan.
SO Psychopharmacology, **(2000 May)** 150 (1) 9-14.
Journal code: 7608025. ISSN: 0033-3158.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200010
ED Entered STN: 20001019
Last Updated on STN: 20001019
Entered Medline: 20001011

L16 ANSWER 9 OF 22 MEDLINE on STN
AN 2000458983 MEDLINE
DN PubMed ID: 10836282
TI Effective open-label treatment of tourette's disorder with olanzapine.
AU Stamenkovic M; Schindler S D; Aschauer H N; De Zwaan M; Willinger U; Resinger E; Kasper S
CS Department of General Psychiatry, University Hospital for Psychiatry

Vienna, Austria.
SO International clinical psychopharmacology, **(2000 Jan)** 15 (1) 23-8.
Journal code: 8609061. ISSN: 0268-1315.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200009
ED Entered STN: 20001005
Last Updated on STN: 20001005
Entered Medline: 20000925

L16 ANSWER 10 OF 22 MEDLINE on STN
AN 2000434005 MEDLINE
DN PubMed ID: 10843455
TI Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor **antagonist** (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat.
AU Kodama M; Takimoto Y
CS Department of Urology, Nihon University School of Medicine, Surugadai Nihon University Hospital, Tokyo, Japan.
SO International journal of urology : official journal of the Japanese Urological Association, **(2000 Jun)** 7 (6) 231-5.
Journal code: 9440237. ISSN: 0919-8172.
CY Australia
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200009
ED Entered STN: 20000928
Last Updated on STN: 20000928
Entered Medline: 20000921

L16 ANSWER 11 OF 22 MEDLINE on STN
AN 2000397817 MEDLINE
DN PubMed ID: 10774780
TI AT-1015, a novel serotonin (5-HT)2 receptor **antagonist**, blocks vascular and platelet **5-HT2A** receptors and prevents the laurate-induced peripheral vascular lesion in rats.
AU Kihara H; Hirose K; Koganei H; Sasaki N; Yamamoto H; Kimura A; Nishimori T; Shoji M; Yoshimoto R
CS Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., Kawasaki, Japan.
SO Journal of cardiovascular pharmacology, **(2000 Apr)** 35 (4) 523-30.
Journal code: 7902492. ISSN: 0160-2446.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200008
ED Entered STN: 20000824
Last Updated on STN: 20000824
Entered Medline: 20000816

L16 ANSWER 12 OF 22 MEDLINE on STN
AN 2000329696 MEDLINE
DN PubMed ID: 10869889
TI Effects of serotonin and serotonergic agonists and **antagonists** on the production of interferon-gamma and interleukin-10.
AU Kubera M; Kenis G; Bosmans E; Scharpe S; Maes M
CS Clinical Research Center for Mental Health, Anwerp, Belgium.
SO Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, **(2000 Jul)** 23 (1) 89-98.
Journal code: 8904907. ISSN: 0893-133X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200007
ED Entered STN: 20000728
Last Updated on STN: 20000728
Entered Medline: 20000717

L16 ANSWER 13 OF 22 MEDLINE on STN
AN 2000328579 MEDLINE
DN PubMed ID: 10870512
TI Effect of fluoxetine on intraocular pressure in the rabbit.
AU Costagliola C; Mastropasqua L; Capone D; Verolino M; Ciancaglini M; Pisanti N
CS Eye Clinic, 2nd University of Naples, Italy.
SO Experimental eye research, **(2000 May)** 70 (5) 551-5.
Journal code: 0370707. ISSN: 0014-4835.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200007
ED Entered STN: 20000720
Last Updated on STN: 20000720
Entered Medline: 20000710

L16 ANSWER 14 OF 22 MEDLINE on STN
AN 2000296143 MEDLINE
DN PubMed ID: 10839333
TI A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
AU Kapur S; Zipursky R; Jones C; Shammi C S; Remington G; Seeman P
CS Department of Psychiatry, University of Toronto, Ontario..
kapur@clarke-inst.on.ca
SO Archives of general psychiatry, **(2000 Jun)** 57 (6) 553-9.
Journal code: 0372435. ISSN: 0003-990X.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200006
ED Entered STN: 20000616
Last Updated on STN: 20000616
Entered Medline: 20000607

L16 ANSWER 15 OF 22 MEDLINE on STN
AN 2000263588 MEDLINE
DN PubMed ID: 10802024
TI Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area.
AU Doherty M D; Pickel V M
CS Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 411 East 69th Street, New York, NY, USA..
mdoherty@mail.med.cornell.edu
NC DA04600 (NIDA)
MH00078 (NIMH)
MH40342 (NIMH)
SO Brain research, **(2000 May 12)** 864 (2) 176-85.
Journal code: 0045503. ISSN: 0006-8993.

CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200007
ED Entered STN: 20000714
Last Updated on STN: 20000714
Entered Medline: 20000703

L16 ANSWER 16 OF 22 MEDLINE on STN
AN 2000245211 MEDLINE
DN PubMed ID: 10781645
TI T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction.
AU Yamada S; Akita H; Kanazawa K; Ishida T; Hirata K; Ito K; Kawashima S; Yokoyama M
CS The First Department of Internal Medicine, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan.
SO Atherosclerosis, **(2000 May)** 150 (1) 143-8.
Journal code: 0242543. ISSN: 0021-9150.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200005
ED Entered STN: 20000613
Last Updated on STN: 20000613
Entered Medline: 20000531

L16 ANSWER 17 OF 22 MEDLINE on STN
AN 2000231225 MEDLINE
DN PubMed ID: 10770456
TI Pharmacologic profile of perphenazine's metabolites.
AU Sweet R A; Pollock B G; Mulsant B H; Rosen J; Sorisio D; Kirshner M; Henteleff R; DeMichele M A
CS Geriatric Psychopharmacology, Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania, USA.. SweetRA@msx.upmc.edu
NC MH 01153 (NIMH)
MH 01509 (NIMH)
MH 55106 (NIMH)
+
SO Journal of clinical psychopharmacology, **(2000 Apr)** 20 (2) 181-7.
Journal code: 8109496. ISSN: 0271-0749.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200006
ED Entered STN: 20000706
Last Updated on STN: 20000706
Entered Medline: 20000628

L16 ANSWER 18 OF 22 MEDLINE on STN
AN 2000226725 MEDLINE
DN PubMed ID: 10763515
TI Vasostabilizing effect of Dotarizine (Ca(2+)-channel blocker) on cerebrovascular reactivity in rabbits.
AU Kuridze N; Czernicki Z; Jarus-Dziedzic K; Jurkiewicz J; Cervos-Navarro J
CS Department of Neurosurgery, Polish Academy of Sciences, Warszaw, Poland.
SO Neurological research, **(2000 Mar)** 22 (2) 229-32.
Journal code: 7905298. ISSN: 0161-6412.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200006
ED Entered STN: 20000616
Last Updated on STN: 20000616
Entered Medline: 20000607

L16 ANSWER 19 OF 22 MEDLINE on STN
AN 2000199683 MEDLINE
DN PubMed ID: 10737422
TI Chronic electroconvulsive shock decreases (+/-) 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane hydrochloride (DOI)-induced wet-dog shake behaviors of dexamethasone-treated rats.
AU Kozuru T; Kagaya A; Takebayashi M; Horiguchi J; Yamawaki S
CS Department of Psychiatry and Neurosciences, Hiroshima University School of Medicine, Japan.
SO Life sciences, **(2000 Feb 18)** 66 (13) 1271-9.
Journal code: 0375521. ISSN: 0024-3205.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200004
ED Entered STN: 20000421
Last Updated on STN: 20000421
Entered Medline: 20000411

L16 ANSWER 20 OF 22 MEDLINE on STN
AN 2000197907 MEDLINE
DN PubMed ID: 10731624
TI Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.
AU Kranzler H R; Modesto-Lowe V; Van Kirk J
CS Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030-2103, USA.
NC K02-AA0239 (NIAAA)
P50-AA03510 (NIAAA)
T32-AA07290 (NIAAA)
+
SO Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, **(2000 May)** 22 (5) 493-503.
Journal code: 8904907. ISSN: 0893-133X.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200005
ED Entered STN: 20000518
Last Updated on STN: 20000518
Entered Medline: 20000509

L16 ANSWER 21 OF 22 MEDLINE on STN
AN 2000193521 MEDLINE
DN PubMed ID: 10727629
TI Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis.
AU Raghavendra V; Kulkarni S K
CS Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
SO Brain research, **(2000 Mar 31)** 860 (1-2) 112-8.
Journal code: 0045503. ISSN: 0006-8993.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals

EM 200006
ED Entered STN: 20000622
Last Updated on STN: 20000622
Entered Medline: 20000615

L16 ANSWER 22 OF 22 MEDLINE on STN
AN 2000184907 MEDLINE
DN PubMed ID: 10721882
TI Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade.
AU Lauterbach E C; Abdelhamid A; Annandale J B
CS Department of Psychiatry and Behavioral Sciences, Neurology Section Mercer University School of Medicine, Macon, GA 31207, USA.
SO Pharmacopsychiatry, **(2000 Jan)** 33 (1) 38-41.
Journal code: 8402938. ISSN: 0176-3679.
CY GERMANY: Germany, Federal Republic of
DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200005
ED Entered STN: 20000518
Last Updated on STN: 20000518
Entered Medline: 20000510

=> D ABS 20

L16 ANSWER 20 OF 22 MEDLINE on STN
AB This study compared the effects of nefazodone, a serotonergic antidepressant, with the opioid **antagonist** naltrexone, and an inactive placebo in 183 alcohol-dependent subjects receiving weekly relapse prevention psychotherapy. Following a single-blind, placebo lead-in period, subjects were randomly assigned to receive study medication, which they took under double-blind conditions for 11 weeks. Naltrexone treatment was associated with significantly more adverse neuropsychiatric and gastrointestinal effects, poorer compliance, and a greater rate of treatment attrition. There were no reliable between-group differences in drinking behavior. These results indicate that nefazodone is not efficacious for treatment of alcohol dependence. Furthermore, the **clinical** utility of naltrexone seems to be limited by its adverse effects, a finding that has important implications for efforts to develop medications to treat alcohol dependence.

=> D ABS 11

L16 ANSWER 11 OF 22 MEDLINE on STN
AB The serotonin (**5-HT2A**) **antagonistic** activities and the protective effect on laurate-induced peripheral vascular lesions of AT-1015, a novel 5-HT2 receptor **antagonist**, were investigated. In platelet aggregation, AT-1015 selectively inhibited in vitro **5-HT2A** receptor-mediated aggregation, and the activity was almost equivalent to that of ketanserin (5-**HT2A**/2C receptor **antagonist**) and 100 times more potent than sarpogrelate (**5-HT2A** receptor **antagonist**). AT-1015 also inhibited **5-HT2A** receptor-mediated aggregation by oral administration in rat, and the dose required for inhibition was equivalent to ketanserin. In a 5-HT-induced vasoconstriction study in rat, AT-1015 slightly reduced maximal contraction and caused a rightward shift of the concentration-response curve (pKB value, 9.5), which was unlike competitive inhibitors such as ketanserin and sarpogrelate (pA2 value, 9.3 and 8.7, respectively). Moreover, the ex vivo inhibitory activity significantly remained after oral administration (1 mg/kg). In the rat peripheral vascular lesion model, AT-1015 (1 mg/kg, p.o.) effectively prevented progression of peripheral lesions, and it was more potent compared with ketanserin, sarpogrelate, and cilostazol. These results suggest that AT-1015 is a potent **5-HT2A** receptor **antagonist**, and its insurmountable **antagonism** may be relevant to its **therapeutic** potential in peripheral vascular disease.

=> D ABS 2

L16 ANSWER 2 OF 22 MEDLINE on STN
AB Six sesquiterpenoids, namely jinkoh-eremol, agarospirol, alpha- and beta-santalols, dehydrocostus lactone and costunolide, isolated from oriental incenses inhibited acetic acid-induced writhing in mice. The incidence of writhing produced by jinkoh-eremol, alpha-santalol and costunolide were revealed by administration of naloxone (mu-, kappa- and delta-**antagonists**). Inhibitory activities of alpha-santalol on opioid receptors were shown only by the delta **antagonist**, but not by the mu- and kappa-**antagonists**. The delta2-**antagonist**, but not the delta-**antagonist**, inhibited the activity of alpha santalol. The mechanism of inhibitory activity on the opioid receptor by alpha-santalol was different from that of morphine. Alpha-santalol was shown to be the most potent of the six as an **antagonist** of dopamine D2 and serotonine **5-HT2A** receptor binding. The effect of alpha-santalol, was the same as that of chlorpromazine as an antipsychotic agent, although alpha-santalol was less potent than chlorpromazine.

=> LOG HOLD
COST IN U.S. DOLLARS SINCE FILE ENTRY 21.37 TOTAL SESSION 21.58

FULL ESTIMATED COST

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:00:36 ON 22 NOV 2005